WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of ...
* Repligen expects sales of TangenX products to achieve double-digit growth and contribute $7.0-$7.5 million in revenue for year 2017 * Acquisition by Repligen was completed through an all cash ...
For decades, therapeutic monoclonal antibody (mAb) production relied on traditional batch-based manufacturing using stainless steel systems. But as biopharmaceutical pipelines grow to meet rising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results